Parallax Volatility Advisers, L.P. Intellia Therapeutics, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $2.48 Million - $4.68 Million	-74,600 Reduced 99.47%	400 $13,000
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $4.04 Million - $5.37 Million	74,900 Added 74900.0%	75,000 $4.2 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $1.06 Million - $2.1 Million	-27,500 Reduced 99.64%	100 $5,000
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $1.32 Million - $1.77 Million	-10,000 Reduced 26.6%	27,600 $3.7 Million
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $2.29 Million - $6.09 Million	37,600 New	37,600 $6.09 Million
Q4 2020 Feb 16, 2021	SELL	$18.83 - $63.53 $674,113 - $2.27 Million	-35,800 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$17.47 - $24.93 $625,426 - $892,494	35,800 New	35,800 $712,000
Q3 2018 Nov 14, 2018	SELL	$25.78 - $32.6 $456,306 - $577,020	-17,700 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$20.02 - $30.79 $354,354 - $544,983	17,700 New	17,700 $483,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $916M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.